Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm

Ocular immune-related adverse events (IrAEs) associated with use of checkpoint inhibitors (CPIs) in cancer therapeutics are relatively rare, occurring in approximately 1% of treated patients. Recognition and early intervention are essential because the degree of tissue damage may be disproportionate...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahzad, Orthi, Thompson, Nicola, Clare, Gerry, Welsh, Sarah, Damato, Erika, Corrie, Philippa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887679/
https://www.ncbi.nlm.nih.gov/pubmed/33633802
http://dx.doi.org/10.1177/1758835921992989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887679/
https://www.ncbi.nlm.nih.gov/pubmed/33633802
http://dx.doi.org/10.1177/1758835921992989

Ejemplares similares